Anti Cancer Medicines
Showing 17–32 of 49 results
-
LUMAKRAS (sotorasib) tablets. Get Access In India
Read more -
MACRILEN (macimorelin) for oral solution. Initial U.S. Approval: 2017
Read more -
NUBEQA (darolutamide) tablets, for oral use. Initial U.S. Approval: 2019
Read more -
ONTRUZANT (trastuzumab-dttb) for injection, for intravenous use Initial U.S. Approval: 2019
Read more -
OPDIVO (nivolumab) injection, for intravenous use Initial U.S. Approval: 2014
Read more -
PARSABIV (etelcalcetide) injection, for intravenous use. Initial U.S. Approval: 2017
Read more -
PERJETA (pertuzumab) Injection, for intravenous use Initial U.S. Approval: 2012
Read more -
PHESGO (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection, for subcutaneous use Initial U.S. Approval: 2020
Read more -
PIQRAY (alpelisib) tablets, for oral use. Initial U.S. Approval: 2019
Read more -
QUZYTTIR (cetirizine hydrochloride injection), for intravenous use. Initial U.S. Approval: 1995
Read more -
RAVICTI (glycerol phenylbutyrate) oral liquid. Initial U.S. Approval: 1996
Read more -
REBLOZYL (luspatercept-aamt) for injection, for subcutaneous use. Initial U.S. Approval: 2019
Read more -
RETEVMO (selpercatinib) capsules
Read more -
ROLVEDON (eflapegrastim-xnst) injection
Read more -
ROZLYTREK (entrectinib) capsules, for oral use Initial U.S. Approval: 2019
Read more -
Soliris (eculizumab) Concentrated solution for intravenous infusion Initial U.S. Approval: 2007
Read more